On September 29, 2026, Bristol Myers Squibb...disclosed safety concerns in its phase 3 clinical trials for admilparant, a drug candidate targeting idiopathic pulmonary fibrosis, after identifying significant risks of liver injury including a patient death linked to acute hepatic injury (Gurufocus) - Sep 30, 2026 - "The identification of liver injury as a significant adverse event, including a fatal case of acute hepatic injury, has prompted the company to revise its clinical trial protocols. These revisions mandate enhanced liver function monitoring and establish clear stopping rules to mitigate drug-induced liver damage risks. This development is critical as it may impact the drug's regulatory approval timeline and market potential, given the seriousness of liver-related adverse effects."
Adverse events • Clinical protocol • Idiopathic Pulmonary Fibrosis
|